Fred Saad¹, Kim Chi², Neil Fleshner³

Canadian Journal of Urology, Vol.11, No.5, pp. 2376-2382, 2004

Abstract Bone metastases are associated with significant skeletal-related morbidity that negatively correlates with quality of life and survival in patients with prostate cancer. Once prostate cancer has metastasized to bone, the median survival of patients is approximately 30 to 53 months; therefore, the chronic consequences of bone complications must be taken into consideration when developing long-term therapeutic strategies in this patient population. In addition to the bone-damaging effects of metastases, bone loss related to long-term hormonal therapy, as well as age-related bone loss, further compromise bone integrity in patients with advanced prostate cancer.
This article reviews the More >

Oren M. Shemtov¹, Sidney B. Radomski², Juanita Crook³

Canadian Journal of Urology, Vol.11, No.6, pp. 2450-2455, 2004

Abstract Purpose: We undertook to determine if any significant differences in the efficacy of sildenafil citrate for erectile dysfunction (ED) exists between patients who have received external beam radiation or brachytherapy for prostate cancer.
Materials and methods: Thirty-one patients who had received external beam radiation and nineteen patients who had received brachytherapy for prostate cancer and were subsequently treated with sildenafil citrate for post-irradiation ED comprised the patient population. A chart analysis was performed to determine either the presence or absence of concomitant risk factors for ED (coronary artery disease, diabetes, hypertension and smoking history) as well as… More >

Eric Winquist¹, John J. Wilson², Mark Dorreen³, Ralph Wong⁴, Derek Jonker⁵, Neil Iscoe⁶

Canadian Journal of Urology, Vol.11, No.6, pp. 2445-2449, 2004

Abstract Objective: To assess the efficacy and tolerability of a 3-week outpatient schedule of intravenous gemcitabine and cisplatin in patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract (TCC).
Patients and methods: A two-stage phase II trial enrolled TCC patients with Karnofsky performance status >60, measurable disease, and adequate organ function. Prior adjunctive chemotherapy was allowed provided it had been completed at least 1 year prior to study entry. Treatment consisted of gemcitabine 1250 mg/m² iv days 1 and 8 plus cisplatin 70 mg/m² day 1 iv repeated every 21 days. The primary outcome… More >

Les Bowles^1,2, Hanna Bialkowska-Hobrzanska^1,2,3,4, Bernard Bukala⁵, Linda Nott⁵, Hassan Razvi^2,5

Canadian Journal of Urology, Vol.11, No.6, pp. 2438-2444, 2004

Abstract Human telomerase reverse transcriptase (hTERT) mRNA expression has been considered a surrogate marker for telomerase activity based on its parallel detection in urological malignancies, including transitional cell carcinoma (TCC) of the bladder. The objective of this study was to prospectively evaluate the diagnostic performance of urine hTERT mRNA marker and urine cytology in the detection of bladder cancer.
The multiplex hTERT/GAPDH (glyceraldehyde-3- phosphate dehydrogenase) reverse transcription polymerase chain reaction (RT-PCR) assay was employed to assess hTERT mRNA expression in urine sediments from 43 patients with clinically apparent TCC undergoing transurethral resection. Tumor grade and pathological stage… More >

Laurence H. Klotz

Canadian Journal of Urology, Vol.11, No.6, pp. 2426-2426, 2004

Abstract This article has no abstract. More >

Neslihan Bukan¹, Sinan Sözen², Ugur Coskun³, Banu Sancak¹, Nazan Günel³, Ibrahim Bozkırlı², Çagrı Senocak²

European Cytokine Network, Vol.14, No.3, pp. 163-167, 2003

Abstract Background: Both interleukin-18 and nitric oxide are multifunctional molecules that are involved in the different steps of carcinogenesis.
Methods: In the present study, we measured serum interleukin-18 and nitric oxide activity in 51 bladder cancer patients with different tumor stage and grade, and in 8 healthy controls. Serum nitrite-nitrate levels were measured as an index of nitric oxide generation.
Results: Serum interleukin-18 levels were significantly higher in bladder cancer patients when compared to the control subjects (p > 0.05). Serum interleukin-18 levels were found to be higher in patients with Ta stage than patients with T1 More >

Daniel J. Caruso, Murali K. Ankem, John Riordan, Joseph G. Barone

Canadian Journal of Urology, Vol.10, No.3, pp. 1910-1911, 2003

Abstract Prune Belly Syndrome developed urinary ascites secondary to forniceal rupture. Treatment consisted of bilateral cutaneous pyelostomies. Even though most children with Prune Belly Syndrome respond to lower urinary tract drainage, a cutaneous pyelostomy may be necessary when the ureters are tortuous and do not drain adequately following bladder decompression. More >

Robert K. Nam¹, Michael A. S. Jewett¹, Murray D. Krahn², Michael A. Robinette¹, John Tsihlias¹, Ants Toi³, Minnie Ho¹, Andrew Evans⁴, Joan Sweet⁴, John Trachtenberg¹

Canadian Journal of Urology, Vol.10, No.3, pp. 1891-1898, 2003

Abstract Background: In Canada, waiting times for cancer care have been increasing, particularly for patients with genitourinary malignancies. We examined whether delay from diagnosis for patients undergoing surgery for clinically localized prostate cancer affects cancer cure rates.
Methods: We conducted a historical cohort study among 645 patients who underwent radical prostatectomy between 1987 and 1997, using biochemical recurrence (PSA elevation) and metastasis as endpoints. We examined whether patients who underwent surgery ≥3 months (delayed surgery group) from the date of diagnosis had reduced recurrence-free survival, compared to patients who had surgery <3 months (early surgery group) from the… More >

R. A. McLellan, C. G. French, D. G. Bell

Canadian Journal of Urology, Vol.10, No.3, pp. 1880-1884, 2003

Abstract Introduction: Bladder cancer is the most common malignant tumor of the urinary system. Tobacco smoking has been implicated as a major risk factor for the development of bladder cancer and Nova Scotia has some of the highest smoking rates in Canada. We examined trends in the incidence of bladder cancer in Nova Scotia between 1980 and 1999.
Materials and methods: Data on incident cases of bladder cancer diagnosed in Nova Scotia over a twenty-year period (1980–1999) were obtained from the Nova Scotia Cancer Registry. The age-standardized incidence and mortality due to bladder cancer was calculated for both… More >

Laurence H. Klotz

Canadian Journal of Urology, Vol.10, No.3, pp. 1819-1820, 2003

Abstract This article has no abstract. More >